Recovery from brain injury: a surprising new drug target

Jonathan Rosand; Pooja Khatri; Jin Moo Lee

doi:10.1016/S1474-4422(19)30117-6

Recovery from brain injury: a surprising new drug target

Jonathan Rosand
, Pooja Khatri
, Jin Moo Lee

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	421-422
Number of pages	2
Journal	The Lancet Neurology
Volume	18
Issue number	5
DOIs	https://doi.org/10.1016/S1474-4422(19)30117-6
State	Published - May 2019

Access to Document

10.1016/S1474-4422(19)30117-6

Cite this

@article{058871805044425fb57ec9ba9aef3da1,

title = "Recovery from brain injury: a surprising new drug target",

author = "Jonathan Rosand and Pooja Khatri and Lee, \{Jin Moo\}",

note = "Funding Information: JR reports grants from the US National Institutes of Health (NIH), relevant to the submitted work, and personal fees from New Beta Innovations and Boehringer Ingelheim, outside the submitted work. PK reports research funding from Genentech, funding for Data Safety and Monitoring Board efforts and consulting to her department from Lumosa, and grants from Cerenovus and Nervive, outside the submitted work. J-ML reports personal fees from Regenera and grants from Biogen and NIH, outside the submitted work.",

year = "2019",

month = may,

doi = "10.1016/S1474-4422(19)30117-6",

language = "English",

volume = "18",

pages = "421--422",

journal = "The Lancet Neurology",

issn = "1474-4422",

number = "5",

}

TY - JOUR

T1 - Recovery from brain injury

T2 - a surprising new drug target

AU - Rosand, Jonathan

AU - Khatri, Pooja

AU - Lee, Jin Moo

N1 - Funding Information: JR reports grants from the US National Institutes of Health (NIH), relevant to the submitted work, and personal fees from New Beta Innovations and Boehringer Ingelheim, outside the submitted work. PK reports research funding from Genentech, funding for Data Safety and Monitoring Board efforts and consulting to her department from Lumosa, and grants from Cerenovus and Nervive, outside the submitted work. J-ML reports personal fees from Regenera and grants from Biogen and NIH, outside the submitted work.

PY - 2019/5

Y1 - 2019/5

UR - https://www.scopus.com/pages/publications/85064004070

U2 - 10.1016/S1474-4422(19)30117-6

DO - 10.1016/S1474-4422(19)30117-6

M3 - Comment/debate

C2 - 30981316

AN - SCOPUS:85064004070

SN - 1474-4422

VL - 18

SP - 421

EP - 422

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 5

ER -

Recovery from brain injury: a surprising new drug target

Access to Document

Other files and links

Cite this